Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients... Show more
ASND's Aroon Indicator triggered a bullish signal on September 11, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 117 similar instances where the Aroon Indicator showed a similar pattern. In 96 of the 117 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 82%.
The Momentum Indicator moved above the 0 level on August 31, 2026. You may want to consider a long position or call options on ASND as a result. In 67 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for ASND just turned positive on August 31, 2026. Looking at past instances where ASND's MACD turned positive, the stock continued to rise in 38 of 57 cases over the following month. The odds of a continued upward trend are 67%.
ASND moved above its 50-day moving average on August 31, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ASND crossed bullishly above the 50-day moving average on September 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 17 of 22 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.
Following a +1.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where ASND advanced for three days, in 187 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 62 cases where ASND's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ASND declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
ASND broke above its upper Bollinger Band on September 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron SMR rating for this company is 12 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 37 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. ASND’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 75 (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.373) is normal, around the industry mean (19.994). P/E Ratio (20.243) is within average values for comparable stocks, (27.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.527). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (13.699) is also within normal values, averaging (427.627).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of drug candidates
Industry Biotechnology